Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT03807921

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Instituto Nacional de Cirugia Cardiaca, Uruguay (from the registry)
Registry
  • NCT NCT03807921
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Uruguay (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03807921. Randomized; single masking; primary purpose treatment. Start 2019-01-01 (actual); primary completion 2019-12-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
Condition
Aortic Valve Stenosis
Condition
Aortic Valve Disease
Condition
Aortic Valve Insufficiency
Condition
Aortic Valve Regurgitation
Intervention (Drug)
Warfarin
Intervention (Drug)
Aspirin
Lead sponsor
Instituto Nacional de Cirugia Cardiaca, Uruguay (class: other)
Collaborator
Universidad de la Republica (class: other)

Record details

Record id
cardio:ct-nct03807921
Content hash
aaa4e0d74fca3ae275bd635ded7a6ed2b2503172d72f1e971cc9049805c21fa0